Q-omics provides the consensus-scored RNY3P8 profile across patient tissues and cancer cell-line models. RNY3P8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RNY3P8 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RNY3P8 RNA expression shows 12,551 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, COAD, and TGCT as cancer lineages where RNY3P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY3P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY3P8 survival associations across molecular data types. RNY3P8 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY3P8 RNA expression–survival associations across cancer types. High RNY3P8 expression shows unfavorable associations in BRCA, LIHC and UCEC, but favorable associations in BLCA, LUAD and LUSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for RNY3P8 RNA expression.
This table summarizes RNY3P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNY3P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY3P8 shows lower tumor expression in COAD, THCA, BLCA, LUAD and UCEC and higher tumor expression in LIHC. The COAD box plot shows higher RNY3P8 RNA expression in normal versus tumor tissue (log2 FC = −0.747, t-test p < 0.001).
This table shows molecular features associated with RNY3P8 in patient tissues and cancer cell lines. In patient samples, RNY3P8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
